FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950141475> ?p ?o ?g. }

• W2950141475 endingPage "e0209392" @default.
• W2950141475 startingPage "e0209392" @default.
• W2950141475 abstract "Purpose Triple negative breast cancer (TNBC) is the most lethal and aggressive subtype of breast cancer. AMP-activated protein kinase (AMPK) is a major energy regulator that suppresses tumor growth, and 1-(3-chloro-4-((trifluoromethyl)thio)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea (FND-4b) is a novel AMPK activator that inhibits growth and induces apoptosis in colon cancer. The purpose of this project was to test the effects of FND-4b on AMPK activation, proliferation, and apoptosis in breast cancer with a particular emphasis on TNBC. Materials and methods (i) Estrogen-receptor positive breast cancer (ER+BC; MCF-7, and T-47D), TNBC (MDA-MB-231 and HCC-1806), and breast cancer stem cells were treated with FND-4b for 24h. Immunoblot analysis assessed AMPK, acetyl-CoA carboxylase (ACC), ribosomal protein S6, cyclin D1, and cleaved PARP. (ii) Sulforhodamine B growth assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h. Proliferation was also assessed by counting cells after 72h of FND-4b treatment. (iii) Cell death ELISA assays were performed after treating ER+BC and TNBC cells with FND-4b for 72h. Results (i) FND-4b increased AMPK activation with concomitant decreases in ACC activity, phosphorylated S6, and cyclin D1 in all subtypes. (ii) FND-4b decreased proliferation in all cells, while dose-dependent growth decreases were found in ER+BC and TNBC. (iii) Increases in apoptosis were observed in ER+BC and the MDA-MB-231 cell line with FND-4b treatment. Conclusions Our findings indicate that FND-4b decreases proliferation for a variety of breast cancers by activating AMPK and has notable effects on TNBC. The growth reductions were mediated through decreases in fatty acid synthesis (ACC), mTOR signaling (S6), and cell cycle flux (cyclin D1). ER+BC cells were more susceptible to FND-4b-induced apoptosis, but MDA-MB-231 cells still underwent apoptosis with higher dose treatment. Further development of FND compounds could result in a novel therapeutic for TNBC." @default.
• W2950141475 created "2019-06-27" @default.
• W2950141475 creator A5002402103 @default.
• W2950141475 creator A5011907117 @default.
• W2950141475 creator A5023436882 @default.
• W2950141475 creator A5053575451 @default.
• W2950141475 creator A5068753759 @default.
• W2950141475 creator A5075073656 @default.
• W2950141475 creator A5081171330 @default.
• W2950141475 date "2019-03-15" @default.
• W2950141475 modified "2023-10-11" @default.
• W2950141475 title "Induction of AMPK activation by N,N’-diarylurea FND-4b decreases growth and increases apoptosis in triple negative and estrogen-receptor positive breast cancers" @default.
• W2950141475 cites W1495274944 @default.
• W2950141475 cites W1563676220 @default.
• W2950141475 cites W1859354334 @default.
• W2950141475 cites W1884424945 @default.
• W2950141475 cites W1969231977 @default.
• W2950141475 cites W1972594681 @default.
• W2950141475 cites W1979000812 @default.
• W2950141475 cites W1982047458 @default.
• W2950141475 cites W1984177335 @default.
• W2950141475 cites W2015501861 @default.
• W2950141475 cites W2030817984 @default.
• W2950141475 cites W2046581895 @default.
• W2950141475 cites W2052048865 @default.
• W2950141475 cites W2059642778 @default.
• W2950141475 cites W2079551052 @default.
• W2950141475 cites W2098241983 @default.
• W2950141475 cites W2108183713 @default.
• W2950141475 cites W2110443482 @default.
• W2950141475 cites W2132413659 @default.
• W2950141475 cites W2136887307 @default.
• W2950141475 cites W2147902297 @default.
• W2950141475 cites W2155598285 @default.
• W2950141475 cites W2321579610 @default.
• W2950141475 cites W2359972779 @default.
• W2950141475 cites W2462514513 @default.
• W2950141475 cites W2508639944 @default.
• W2950141475 cites W2523763608 @default.
• W2950141475 cites W2594356097 @default.
• W2950141475 cites W2615855974 @default.
• W2950141475 cites W2755119609 @default.
• W2950141475 cites W2765261715 @default.
• W2950141475 cites W277845461 @default.
• W2950141475 doi "https://doi.org/10.1371/journal.pone.0209392" @default.
• W2950141475 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6420029" @default.
• W2950141475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30875375" @default.
• W2950141475 hasPublicationYear "2019" @default.
• W2950141475 type Work @default.
• W2950141475 sameAs 2950141475 @default.
• W2950141475 citedByCount "14" @default.
• W2950141475 countsByYear W29501414752019 @default.
• W2950141475 countsByYear W29501414752020 @default.
• W2950141475 countsByYear W29501414752021 @default.
• W2950141475 countsByYear W29501414752022 @default.
• W2950141475 countsByYear W29501414752023 @default.
• W2950141475 crossrefType "journal-article" @default.
• W2950141475 hasAuthorship W2950141475A5002402103 @default.
• W2950141475 hasAuthorship W2950141475A5011907117 @default.
• W2950141475 hasAuthorship W2950141475A5023436882 @default.
• W2950141475 hasAuthorship W2950141475A5053575451 @default.
• W2950141475 hasAuthorship W2950141475A5068753759 @default.
• W2950141475 hasAuthorship W2950141475A5075073656 @default.
• W2950141475 hasAuthorship W2950141475A5081171330 @default.
• W2950141475 hasBestOaLocation W29501414751 @default.
• W2950141475 hasConcept C121608353 @default.
• W2950141475 hasConcept C126322002 @default.
• W2950141475 hasConcept C134018914 @default.
• W2950141475 hasConcept C184235292 @default.
• W2950141475 hasConcept C185592680 @default.
• W2950141475 hasConcept C190283241 @default.
• W2950141475 hasConcept C199835354 @default.
• W2950141475 hasConcept C2780110267 @default.
• W2950141475 hasConcept C2780124434 @default.
• W2950141475 hasConcept C29537977 @default.
• W2950141475 hasConcept C502942594 @default.
• W2950141475 hasConcept C530470458 @default.
• W2950141475 hasConcept C55493867 @default.
• W2950141475 hasConcept C62112901 @default.
• W2950141475 hasConcept C71924100 @default.
• W2950141475 hasConcept C84606932 @default.
• W2950141475 hasConcept C97029542 @default.
• W2950141475 hasConceptScore W2950141475C121608353 @default.
• W2950141475 hasConceptScore W2950141475C126322002 @default.
• W2950141475 hasConceptScore W2950141475C134018914 @default.
• W2950141475 hasConceptScore W2950141475C184235292 @default.
• W2950141475 hasConceptScore W2950141475C185592680 @default.
• W2950141475 hasConceptScore W2950141475C190283241 @default.
• W2950141475 hasConceptScore W2950141475C199835354 @default.
• W2950141475 hasConceptScore W2950141475C2780110267 @default.
• W2950141475 hasConceptScore W2950141475C2780124434 @default.
• W2950141475 hasConceptScore W2950141475C29537977 @default.
• W2950141475 hasConceptScore W2950141475C502942594 @default.
• W2950141475 hasConceptScore W2950141475C530470458 @default.
• W2950141475 hasConceptScore W2950141475C55493867 @default.
• W2950141475 hasConceptScore W2950141475C62112901 @default.
• W2950141475 hasConceptScore W2950141475C71924100 @default.
• W2950141475 hasConceptScore W2950141475C84606932 @default.

• next